174 related articles for article (PubMed ID: 8677079)
1. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
Sutton G; Blessing JA; Park R; DiSaia PJ; Rosenshein N
Obstet Gynecol; 1996 May; 87(5 Pt 1):747-50. PubMed ID: 8677079
[TBL] [Abstract][Full Text] [Related]
2. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Sutton GP; Blessing JA; DeMars LR; Moore D; Burke TW; Grendys EC
Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; McGuire WP; Patton T; Look KY
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
Sutton GP; Blessing JA; Rosenshein N; Photopulos G; DiSaia PJ
Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck.
Huber MH; Lippman SM; Benner SE; Shirinian M; Dimery IW; Dunnington JS; Hong WK
Am J Clin Oncol; 1996 Aug; 19(4):379-82. PubMed ID: 8677909
[TBL] [Abstract][Full Text] [Related]
9. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group.
Pawinski A; Tumolo S; Hoesel G; Cervantes A; van Oosterom AT; Boes GH; Pecorelli S
Eur J Obstet Gynecol Reprod Biol; 1999 Oct; 86(2):179-83. PubMed ID: 10509788
[TBL] [Abstract][Full Text] [Related]
11. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
12. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Barrett RJ; McGehee R
Am J Obstet Gynecol; 1992 Feb; 166(2):556-9. PubMed ID: 1536229
[TBL] [Abstract][Full Text] [Related]
14. Gynecologic Oncology Group studies with ifosfamide.
Sutton GP; Blessing JA; Manetta A; Homesley H; McGuire W
Semin Oncol; 1992 Dec; 19(6 Suppl 12):31-4. PubMed ID: 1485172
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
16. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; DiSaia PJ; McGuire WP
Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
Walters RS; Holmes FA; Valero V; Esparza-Guerra L; Hortobagyi GN
Am J Clin Oncol; 1998 Aug; 21(4):413-5. PubMed ID: 9708645
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Homesley HD; Malfetano JH
Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide in the treatment of soft tissue sarcomas.
Connelly EF; Budd GT
Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
